Filing Flows › PTC Therapeutics (PTCT) › Q3 2026
PTC Therapeutics (PTCT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
PTC Therapeutics (PTCT) reported revenue of $358M for the third quarter 2026 (Q3 2026), +70% from a year earlier and -0.8% from the quarter before. Operating margin was 7.0%, net loss $51.7M (14.4% of revenue).
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $358M | -0.8% | +70% |
| Operating profit | $25.1M | -83% | +733% |
| Net earnings | −$51.7M | -162% | -425% |
| Operating cash flow | −$25.3M | -120% | — |
What changed
Revenue was $357.8M in Q3 2026, up 70% year over year and down 1% from the previous quarter. Sephience was the largest line at 51% of revenue. Sephience added $162.3M year over year (up 830%), 111% of the total change. Collaboration and license revenue declined 98%.
Operating profit was $25.1M, a 7.0% margin (up 5.6 points year over year). Of the extra revenue versus Q3 2025, 15% reached operating profit, above the 1% margin then. Total costs grew 60% against revenue growth of 70%. The fastest-growing cost line was Other operating costs (+519%). The quarter ended with a net loss of $51.7M, after a profit of $83.5M the previous quarter. Net interest and other expense of $66.2M was the main reason.
Operating cash flow was −$25.3M. Non-cash charges added back $16.8M of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items used $14.3M. Capital expenditures of $2.7M exceeded it, leaving free cash flow of −$28.0M.
Questions
What was PTC Therapeutics' revenue in the third quarter 2026?
PTC Therapeutics (PTCT) reported revenue of $358M for the third quarter 2026 (Q3 2026), +70% from a year earlier and -0.8% from the quarter before.
Was PTC Therapeutics profitable in the third quarter 2026?
Operating profit was $25.1M (7.0% of revenue) and net loss $51.7M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.